Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845397 | 0.79 | KDM4E (0.43) | MAPK1ALOX12PGRMEN1HSP90AA1 | |
| SCHEMBL22845276 | 0.78 | REN (0.41) | PGRKDM4CMEN1KMT2AREN | |
| SCHEMBL22845300 | 0.77 | KDM4C (0.48) | DYRK1AKDM4CMAPTKMT2AALDH1A1 | |
| SCHEMBL22845203 | 0.77 | KDM5A (0.42) | ALOX12PGRMEN1HSP90AA1MAPT | |
| SCHEMBL22845222 | 0.76 | REN (0.41) | ALOX12PGRDYRK1AKDM4CREN | |
| SCHEMBL22845485 | 0.75 | ALDH1A1 (0.41) | MAPK1ALOX12PGRALDH1A1KDM5A | |
| SCHEMBL22172011 | 0.72 | KDM4C (0.47) | MAPK1ALOX12DYRK1AKDM4CREN | |
| SCHEMBL22172017 | 0.69 | KDM4E (0.53) | MAPK1ALOX12PGRDYRK1AKDM4C | |
| SCHEMBL4190441 | 0.69 | SMN1; SMN2 (0.43) | MAPK1ALOX12DYRK1AKDM4CMEN1 | |
| SCHEMBL15428469 | 0.67 | KDM4E (0.67) | DYRK1ARENALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976618-A1 | TRICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
| WO-2020243199-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPK1 2170/4885ALOX12 2309/4885PGR 2446/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MAPK1 2170/4885ALOX12 2309/4885PGR 2446/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPK1 2170/4885ALOX12 2309/4885PGR 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.